NeuroPace Reports 17% Revenue Growth to $22.8 Million in Q2 2026

NeuroPace, Inc. reported its financial results for the second quarter of 2026, revealing a revenue increase of 17% to $22.8 million, compared to $19.5 million in the same period last year. For the first half of 2026, revenue rose by 19% to $44.8 million from $37.8 million in the prior year. The company attributed this growth primarily to an increase in the number of RNS System units sold, driven by a higher volume of initial implants and replacements. However, the cost of goods sold also increased, leading to a slight decrease in gross margin from 83.1% to 82.8% for the quarter.

In terms of operational performance, NeuroPace's total operating expenses for the second quarter were $24.0 million, a slight decrease from $24.4 million in the previous year. The company reported a loss from continuing operations of $5.1 million, an improvement from a loss of $8.2 million in the same quarter of 2025. The net loss for the quarter was $6.2 million, down from $10.0 million year-over-year. The company’s accumulated deficit as of June 30, 2026, stood at $565.3 million, reflecting ongoing investments in research and development and commercial activities.

NeuroPace has also undergone significant strategic changes, including the cessation of its DIXI Medical product operations, which were classified as discontinued operations effective June 30, 2026. This decision followed the expiration of an exclusive distribution agreement with DIXI Medical on September 30, 2025. The company has since returned all remaining inventory and does not expect to generate further revenue from this product line. The impact of this strategic shift is expected to affect future revenue growth and financial performance.

The company’s operational metrics indicate a focus on expanding its market presence. As of June 30, 2026, NeuroPace had 220 employees and is actively working to increase its sales force to drive adoption of its RNS System. The company is also pursuing expanded FDA labeling for its device to treat additional patient populations, including those with generalized epilepsy and pediatric patients. However, the recent correspondence from the FDA regarding the non-approvability of a Premarket Approval Supplement (PMA-S) for the RNS System has raised concerns about potential delays in these efforts.

Looking ahead, NeuroPace anticipates continued investment in research and development, clinical studies, and commercial activities to support its growth strategy. The company believes its existing cash, cash equivalents, and short-term investments of $51.7 million will sustain operations for at least the next 12 months. However, it acknowledges the need for additional funding to support ongoing operations and potential future growth initiatives, which may include equity or debt financing. The company remains committed to enhancing its product offerings and expanding its market reach, despite the challenges posed by competitive pressures and regulatory hurdles.